Tumor-Treating Fields Applications in Oncology

Tumor-Treating Fields (TTFields) represent a non-invasive anticancer modality in which low-intensity, intermediate-frequency alternating electric fields are applied to tumour regions via transducer arrays. These fields impose biophysical forces on polar intracellular structures, most notably the mitotic spindle, thereby disrupting proper chromosome segregation and inducing mitotic catastrophe. Clinically approved for glioblastoma and under investigation in mesothelioma, ovarian, pancreatic and lung cancers, TTFields have been shown to extend progression-free and overall survival when added to standard therapies. Beyond mitotic interference, emerging evidence indicates multifaceted mechanisms of action, including impaired DNA repair, altered membrane permeability, induction of immunogenic cell death and modulation of cell signalling pathways. Technological advances range from wearable surface arrays to implantable, ultrasound-powered hydrogel devices, aimed at improving field delivery and patient compliance. Ongoing research focuses on optimising field parameters, elucidating resistance mechanisms such as autophagy upregulation, and identifying synergistic combinations with chemotherapy, radiation and targeted inhibitors. Globally, TTFields therapy has spurred multidisciplinary collaborations involving engineers, biologists and clinicians, driving translational efforts towards broader applications and personalised treatment regimens.

Research from Nature Portfolio

Seminal investigations have confirmed the core biophysical effect of TTFields on mitosis. A foundational study demonstrated that alternating electric fields decrease the ratio of polymerised to total tubulin, preventing correct mitotic spindle assembly. This disruption leads to abnormal chromosome segregation, multinucleation and caspase-dependent apoptosis, with treatment efficacy correlating to cell division rate and exposure duration. These insights solidify the mitotic spindle as a primary target and inform decisions on field intensity and frequency for clinical protocols.

Tumor-Treating Fields Applications in Oncology publication trend

The graph below shows the total number of articles in tumor-treating fields applications in oncology across all publications each year (not limited to Nature Index journals).

Technical terms

Tumor-Treating Fields (TTFields): Low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz) alternating electric fields delivered via transducer arrays to disrupt cancer cell division.

Mitotic spindle: Microtubule-based apparatus responsible for equal chromosome segregation during cell division.

PI3K/AKT signalling pathway: Intracellular cascade regulating cell growth, survival and metabolism, often dysregulated in cancer.

Hydrogel: Hydrophilic polymer network capable of retaining water, used to form biocompatible interfaces for device implantation.

Ultrasound-powered generator: Device converting acoustic energy into electrical power to deliver alternating fields without external wiring.

References

1. Implantable Ultrasound‐Powered MXene/PVA Hydrogel‐Based Generator for Treatment of Glioblastoma. Advanced Science (2024).
2. Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields). Cell Death & Disease (2025).
3. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Scientific Reports (2015).
4. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunology, Immunotherapy (2020).
5. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discovery (2018).
6. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death & Disease (2018).
7. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiation Oncology (2017).
8. Tumour treating fields therapy for glioblastoma: current advances and future directions. British Journal of Cancer (2020).